RHOF and acute myeloid leukemia: A similar prognostic impact of RhoF expression was also present in AML favorable patients (median 33.5 vs. 4.5 months, P<0.001, Figure 6A) and intermediate/poor patients (median 19.0 vs. 10.0 months, P=0.02, Figure 6B) with AML stratified according to their risk.